Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.83 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | NOS2 | P35228 | 5/20 | 0.50 |
| ▸ | NOS3 | P29474 | 3/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL1671166 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL27844690 | 0.92 | GSR (0.83) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL28184141 | 0.92 | GSR (0.83) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL28080783 | 0.91 | GSR (0.91) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL31541159 | 0.91 | GSR (0.91) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL18396695 | 0.91 | GSR (0.91) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL18396696 | 0.91 | GSR (0.91) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL8613373 | 0.91 | GSR (1.00) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL9439278 | 0.91 | GSR (1.00) | GSRARG2ARG1NOS1NOS2 | |
| Lysine SCHEMBL3359527 | 0.91 | GSR (1.00) | GSRARG2ARG1NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954370-B1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC (JP) | 2024-05-29 | — | — | EP | claimed |
| CN-114126609-B | Novel therapeutic agent for prototheca | 株式会社赛轮制药 | 2024-01-02 | — | — | CN | claimed |
| US-20220142987-A1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC. (JP) | 2022-05-12 | — | — | US | claimed |
| US-11324728-B2 | Dosing regimens for the treatment of fungal infections | SEREN PHARMACEUTICALS INC. (JP) | 2022-05-10 | — | — | US | claimed |
| US-20200316033-A1 | DOSING REGIMENS FOR THE TREATMENT OF FUNGAL INFECTIONS | SEREN PHARMACEUTICALS INC. (JP) | 2020-10-08 | — | — | US | claimed |
| EP-3954370-B1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-114126609-B | Novel therapeutic agent for prototheca | 株式会社赛轮制药 | 2024-01-02 | — | — | CN | disclosed |
| CN-116987465-A | Adhesive based on crosslinked polyvinylidene fluoride coated mesoporous carbon nanomaterial, preparation method thereof and electrode | 惠州普赛达新材料有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-3998109-A1 | NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE | Seren Pharmaceuticals Inc. (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-20220142987-A1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11324728-B2 | Dosing regimens for the treatment of fungal infections | SEREN PHARMACEUTICALS INC. (JP) | 2022-05-10 | — | — | US | disclosed |
| CN-114126609-A | Novel therapeutic agent for prototheca disease | 株式会社赛轮制药 | 2022-03-01 | — | — | CN | disclosed |
| WO-2021006317-A1 | NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE | 株式会社セレンファーマ | 2021-01-14 | — | — | WO | disclosed |
| WO-2020209215-A1 | ANTI-FUNGAL AGENT | 株式会社セレンファーマ | 2020-10-15 | — | — | WO | disclosed |
| US-20200316033-A1 | DOSING REGIMENS FOR THE TREATMENT OF FUNGAL INFECTIONS | SEREN PHARMACEUTICALS INC. (JP) | 2020-10-08 | — | — | US | disclosed |
| CN-111281979-A | Novel cationic polyphosphazene compounds, polyphosphazene-drug conjugate compounds and methods for preparing same | CN 制药株式会社 | 2020-06-16 | — | — | CN | disclosed |
| CN-106459420-B | Novel cationic polyphosphazene compounds, polyphosphazene-drug conjugate compounds and methods for preparing same | CN制药株式会社 | 2020-03-27 | — | — | CN | disclosed |
| CN-106459420-A | Novel cationic polyphosphazene compounds, polyphosphazene-drug conjugate compounds and methods for preparing same | CN制药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| EP-1877403-A1 | MONO-LYSINE SALTS OF AZOLE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006118351-A1 | MONO-LYSINE SALTS OF AZOLE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142987-A1 | ANTI-FUNGAL AGENT | ERG28, CYP51A1, GANAB | GSR 1182/4885ARG2 142/4885ARG1 127/4885 |
| US-11324728-B2 | Dosing regimens for the treatment of fungal infections | DPM1, ERG28, CYP51A1 | GSR 2866/4885ARG2 1006/4885ARG1 319/4885 |
| US-20200316033-A1 | DOSING REGIMENS FOR THE TREATMENT OF FUNGAL INFECTIONS | DPM1, ERG28, CYP51A1 | GSR 2866/4885ARG2 1006/4885ARG1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.